A brief post argues buyers need accurate information on peptides because a lot of the popular messaging is misleading.
Recap by typeshit. Post by Facebook on Facebook.
A shared explainer on how eating habits and food choices matter once you begin a GLP-1 medication. General guidance, no new findings.
Williams explains how retatrutide's glucagon pathway works and cautions that knockoff Reta sold online is a real risk. FDA approval could come in late 2027 or 2028.
Men's Journal reports the coroner's findings on the cause of Norton's death, with the dose detail coming from the coroner rather than earlier speculation.
Coroner David Ryan found Norton had been taking double his prescribed dose and urged Australia's TGA to tighten rules on peptides, limiting them to clinical trials.
A general piece on how GLP-1 drugs like Ozempic and Wegovy reshaped weight management in the US. Light on new details.
The broker says Laurus beat 2QFY27 estimates on EBITDA and profit, with its CDMO pipeline and peptide work driving the higher forecasts.
Loading…